10.1016/j.jpha.2023.07.001 [DOI] [PMC free article] [PubMed] [Google Scholar] 119.Venkataraman B, Almarzooqi S, Raj V, Bhongade BA, Patil RB, Subramanian VS, Attoub S, Rizvi TA, Adrian TE, Subramanya SB
Many reports using polyclonal antisera were unable to detect GLP-1R protein in ventricular cardiomyocytes leaded to the revaluation of those earlier reports
Tirzepatide and semaglutide work through different mechanisms, have different half-lives, and produce different physiological responses
This suggests that the addition of glucagon agonism to GIP and/or GLP agonism may result in greater efficacy in people with NAFLD/NASH, Dr